Grifols, S.A. (GRFE.XC)
| Previous close | 9.07 |
| Open | 9.07 |
| Bid | 8.61 x N/A |
| Ask | 9.70 x N/A |
| Day's range | 9.07 - 9.07 |
| 52-week range | 6.62 - 15.78 |
| Volume | |
| Avg. volume | 431 |
| Market cap | 4.934B |
| Beta (5Y monthly) | 0.67 |
| PE ratio (TTM) | 100.77 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 03 Jun 2021 |
| 1y target est | N/A |
- GlobeNewswire
Grifols’ Biotest to achieve USD 1 billion in US sales of Yimmugo® over next seven years
Biotest, a Grifols Group company, is expected to launch its recently FDA-approved intravenous immunoglobulin in the U.S. in first quarter 2025 Yimmugo will be distributed by Kedrion in the U.S. as part of a broader Group channel strategy, with Grifols focusing on continued growth of its current portfolio for this market It adds to Grifols’ strong franchise of intravenous and subcutaneous immunoglobulins to meet growing patient demand for these therapeutics Yimmugo will be followed by other prote
- GlobeNewswire
Grifols completes sale of a 20% equity stake in SRAAS and forges strategic alliance with Haier Group
With today’s announcement of the transaction completion, Grifols and Haier Group will work together through Shanghai RAAS (SRAAS) to drive synergies that enhance China’s healthcare systemThrough a share purchase agreement Grifols has sold a 20% equity stake in SRAAS to Haier Group for RMB 12.5 billion (approximately EUR 1.6 billion)Grifols and SRAAS extend their exclusive albumin distribution agreement over the next 10 years, and SRAAS has the option to prolong it through 2044Grifols will use al
- GlobeNewswire
Grifols’ Biotest receives FDA approval for innovative Yimmugo® immunoglobulin to treat primary immunodeficiencies
With Biotest-developed Yimmugo, Grifols adds to its remarkable franchise of intravenous and subcutaneous immunoglobulins to meet strong demand Yimmugo, already approved for production and marketing in Europe, is the first U.S.-approved medicine in Biotest’s portfolio and is manufactured with an innovative process at Biotest’s new FDA-certified ‘Next Level’ facility U.S. approval of Yimmugo paves the way for other Biotest proteins in late-stage development, including fibrinogen and trimodulin Lau
